Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA
Recorded on December 28, 2018
The conversation continues with Dr. Richardson in Part II of a two part episode on myeloma by describing the phases of treatment: induction remission therapy, consolidation and maintenance. Dr. Richardson provides an in-depth view of real-world issues patients experience, describes combination drug therapies and new treatments, addresses the clinical benefit of transplant for individual patients and the difference between tandem and autotransplant, and the important role of the multidisciplinary healthcare team.
Paul Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute